Vincerx Pharma Inc (VINC)
0.70
-0.02
(-2.78%)
USD |
NASDAQ |
May 20, 11:14
Vincerx Pharma Cash from Financing (TTM): 0.116M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.116M |
| December 31, 2023 | 0.114M |
| September 30, 2023 | 0.134M |
| June 30, 2023 | 0.134M |
| March 31, 2023 | 0.283M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.28M |
| September 30, 2022 | 0.525M |
| June 30, 2022 | 48.02M |
| March 31, 2022 | 88.45M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.114M
Minimum
Dec 2023
88.45M
Maximum
Mar 2022
15.34M
Average
0.28M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| Trxade Health Inc | 1.406M |
| MyMD Pharmaceuticals Inc | 13.07M |
| Acrivon Therapeutics Inc | -1.726M |
| Ligand Pharmaceuticals Inc | -46.99M |
| Regulus Therapeutics Inc | 105.73M |